Division of Endocrinology and Metabolism, Capa, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, 34090, Istanbul, Turkey.
Department of Pathology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Pituitary. 2018 Aug;21(4):347-354. doi: 10.1007/s11102-018-0877-3.
To assess baseline T2-weighted signal intensity (T2-WSI) of functional pituitary adenomas (FPA), and to investigate the relationship of baseline T2-WSI with clinical features, histopathological granulation patterns, and response to treatment in patients with acromegaly, prolactinoma and Cushing's disease (CD).
Somatotroph adenomas (n = 87), prolactinomas (n = 78) and corticotroph adenomas (n = 29) were included in the study. Baseline T2-WSI findings (grouped as hypo-, iso- and hyperintense) were compared with hormone levels, tumor diameter, granulation patterns and response to treatment.
Somatotroph adenomas were mostly hypointense (53%), prolactinomas were dominantly hyperintense (55%), and corticotroph adenomas were generally hyperintense (45%). Hyperintense somatotroph adenomas were larger in size with sparsely granulated pattern and tumor shrinkage rate was lower after somatostatin analogues (SSA) (p = 0.007, p = 0.035, p = 0.029, respectively). T2 hypointensity was related with higher baseline IGF-1% ULN (upper limit of normal) levels and a better response to SSA treatment (p = 0.02, p = 0.045, respectively). In female prolactinomas, hyperintensity was correlated with a smaller adenoma diameter (p = 0.001). Hypointense female prolactinomas were related to younger age at diagnosis, higher baseline PRL levels and dopamine agonist (DA) resistance (p = 0.009, p = 0.022, p < 0.001, respectively). Hyperintense corticotroph adenomas were related to larger adenoma size and sparsely granulated pattern (p = 0.04, p = 0.017, respectively). There was no significant difference in the recurrence with T2WSI in CD.
Baseline hypointense somatotroph adenomas show a better response to SSA, whereas hypointensity was related to DA resistance in female prolactinomas.
评估功能性垂体腺瘤(FPA)的基线 T2 加权信号强度(T2-WSI),并探讨其与肢端肥大症、催乳素瘤和库欣病(CD)患者的临床特征、组织病理学颗粒模式和治疗反应之间的关系。
纳入研究的生长激素腺瘤(n=87)、催乳素瘤(n=78)和促肾上腺皮质激素腺瘤(n=29)。将基线 T2-WSI 表现(分为低、等和高信号)与激素水平、肿瘤直径、颗粒模式和治疗反应进行比较。
生长激素腺瘤主要呈低信号(53%),催乳素瘤主要呈高信号(55%),促肾上腺皮质激素腺瘤通常呈高信号(45%)。高信号生长激素腺瘤体积较大,颗粒稀疏,生长抑素类似物(SSA)治疗后肿瘤缩小率较低(p=0.007,p=0.035,p=0.029)。T2 低信号与较高的基线 IGF-1%ULN(正常上限)水平和对 SSA 治疗的更好反应相关(p=0.02,p=0.045)。在女性催乳素瘤中,高信号与较小的腺瘤直径相关(p=0.001)。低信号女性催乳素瘤与诊断时年龄较小、较高的基线 PRL 水平和多巴胺激动剂(DA)抵抗相关(p=0.009,p=0.022,p<0.001)。高信号促肾上腺皮质激素腺瘤与较大的腺瘤大小和稀疏颗粒模式相关(p=0.04,p=0.017)。在 CD 中,T2WSI 与复发之间无显著差异。
基线低信号生长激素腺瘤对 SSA 反应更好,而低信号与女性催乳素瘤中的 DA 抵抗有关。